NCT00650793View on ClinicalTrials.gov

A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia

PHASE3CompletedINTERVENTIONAL

Enrollment

473

Participants

Timeline

Start Date

March 31, 2004

Study Completion Date

February 28, 2006

Conditions

Schizophrenia

Interventions

DRUG

Extended Release OROS® Paliperidone

All Listed Sponsors

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00650793 - A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia | Biotech Hunter | Biotech Hunter